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INTRODUCTION
I am honored to be chosen by the Hong Kong Society
of Nephrology to deliver the first Professor Richard Yu
Endowment Fund Lecture. Professor Yu first introduced
me to nephrology when I was a 3rd year medical student
in 1973. His advice has been most valuable to my career
development and administrative role in the Hong Kong
College of Physicians. In fact, Professor Yu represents
the first generation of clinician–scientist in Hong Kong,
bridging the art of medicine and the science of
physiology.
Previously, genuine clinician–scientists were rare
in Hong Kong. In North America or Europe, this title
usually refers to those with both MD (or MBBS) and
PhD training. Normally, they spend 30–50% of their
time in clinical medicine with direct patient contact,
and the remaining time is spent in research, either on
laboratory work or clinical research. This arrangement
is possible in those countries due to the establishment
of academic track with tenure in university-affiliated
hospitals and also the sizable research grants that may
support part of their salaries. Such a career structure
was virtually non-existent in Asia in the past, even in
Japan. One may ask what is the attraction of being a
clinician–scientist? Why not just practise as a full-time
clinician or, likewise, a full-time scientist? The
attraction of being a clinician–scientist lies in his/her
ability to transcribe a mechanistic concept and to
translate it into clinical practice. Vice versa, a clinician–
scientist often identifies a clinical problem and tries to
explore alternate means to solve the puzzle by studying
the pathophysiologic basis of the issue. More often then
usual, a scientist, per se, studies an issue in depth based
on personal interest with less concern on the practical
application. For most practising clinicians, they
understand the crux of the clinical issue but are often
frustrated by the limited options of effective therapy.
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I will give two examples to illustrate how, with this
information, treatment strategies can possibly be
devised to target the upstream and downstream events
of the pathologic cascade. The conditions I choose are
IgA nephropathy and adipocytes in peritoneal dialysis.
IGA NEPHROPATHY
IgA nephropathy (IgAN), an immune-complex
mediated glomerulonephritis, is the most common
primary glomerulonephritis worldwide. The disease is
characterized by predominant IgA deposition in the
glomerular mesangium and is accompanied by a variety
of histopathologic lesions. Although IgAN was earlier
considered to be a benign condition, its substantial risk
of progression to end-stage renal failure (ESRF) is now
well recognized. About 30–40% of patients with IgAN
develop ESRF within 30 years after the first clinical
presentation. IgAN runs a highly variable clinical
course ranging from a totally benign condition to
rapidly progressive renal failure. In most patients, it
exhibits an indolent and slowly progressive course that
is often associated with tubulointerstitial damage.
A subgroup of IgAN with severe tubulointerstitial
atrophy is often associated with the most rapid
progression to ESRF. IgA nephropathy, among all the
primary glomerular diseases, is often the major cause
of ESRF in patients in renal replacement programs.
With clinical observations of early mesangial IgA
deposition that leads to subsequent recurrence of IgAN
in renal allograft and the spontaneous recovery of
kidney from IgAN patient transplanted to non-IgAN
recipient, nephrologists now recognize that IgAN is a
disease due to anomalies of the IgA molecule and the
kidneys are innocent bystanders. Recurrent IgAN
occurs in no less than 20% of IgAN patients receiving
a renal allograft.
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The deposited IgA in human IgAN is almost
exclusively the IgA1 subclass. IgA1 molecules from
patients with IgAN display altered O-glycan structure
with a defect in galactosylation of IgA1 and also over-
sialylation which have been speculated to result in
pathologic implications. The consequences of this
abnormality are the defective clearance of these
“abnormal IgA” from the circulation and the direct
interaction of the abnormal IgA with the mesangial
cells. Interestingly, circulating immune complexes
containing aberrantly glycosylated IgA1 affect
proliferation of mesangial cells in vitro. We have
demonstrated increased sialylation of IgA1 (α2-3 linked
to galactose) of polymeric IgA1 in IgAN. This
abnormality of IgA1 could also have considerable
implications on the pathogenesis of IgAN, because the
masking effect of sialic acid may hinder the hepatic
clearance of polymeric IgA1. An increase in the
sialylated content also renders the polymeric IgA from
patients with IgAN more anionic, which contributes to
the selective glomerular deposition of polymeric IgA1
via electrostatic interactions.
With the difficult ies in manipulat ing the
carbohydrate moieties in the O-glycan of the IgA
molecule, we turn our attention to the downstream
portion of the inflammatory cascade following
mesangial IgA deposition in IgAN. We focus on the
renin–angiotensin system (RAS) that is involved in
the development of progressive renal fibrosis in
IgAN. Local angiotensin II (AngII) hyperactivity
has been demonstrated in IgAN patients. We have
previously demonstrated that IgA from IgAN patients
is capable of upregulating transforming growth
factor-β(TGF-β) production via increased AngII
release by mesangial cells following binding to
polymeric IgA (pIgA). We have also demonstrated
an altered AngII receptor subtype-1 (ATR1)
expression in mesangial cells in response to raised
intrarenal AngII in IgAN. Furthermore, there is a
defective counterbalance of ATR1 by AngII receptor
subtype-2 (ATR2) as the intrarenal AngII con-
centration is insufficient to upregulate mesangial
ATR2 expression in IgAN. Hence, the imbalance of
ATR1 and ATR2 activities in mesangial cells
following exposure to pIgA may play a significant
pathogenetic role in glomerular inflammation in
IgAN.
In contrast, the mechanism of tubulointerstitial
damage differs from that of mesangial injury in IgAN.
We have demonstrated no binding of IgA to and
absence of IgA receptors in renal tubular cells. The
tubulointerstitial damage in IgAN is an indirect sequel
due to a novel glomerulotubular cross-talk mediated
through soluble factors (predominantly tumor necrosis
factor-α [TNF-α]) released by mesangial cells following
IgA deposition.
We also documented that there is constitutive
expression of ATR1 and ATR2 in renal tubules with
increased expression in IgAN. These receptors are
upregulated after stimulation with mediators derived
from mesangial cells following IgA deposition.
Dissociation in tubular expression of AngII receptors
is evident by the time course of in vitro experiments of
cultured renal tubular cells incubated with mediators
derived from mesangial cells in IgAN. Our cell culture
data suggest the following events that lead to
tubulointerstitial injury. TNF-α in the glomerular
filtrate induces a rapid and early increase in the level
of interleukin (IL)-6 that in turn upregulates ATR1 and
ATR2 expression in “primed tubular cells”. Increased
AngII production through increased AngII and its
receptor binding could further upregulate the production
of AngII. ATR1 and ATR2 mediate proinflammatory
and apoptotic effects in tubular cells, respectively.
Apoptosis mediated by ATR2 counterbalances the
growth-stimulatory effects of AngII through ATR1 in
proximal tubular cells. ATR2 only counteracts the
ATR1-mediated signal transduction pathway of
mitogen-activated protein kinase but not protein kinase
C. Our preliminary in vitro data clearly show that
sequential administration of losartan (an ATR1 blocker)
followed by PD123319 (an ATR2 blocker) is effective
in reducing early inflammatory responses and
preventing late onset of apoptosis caused by ATR2
overexpression.
In conclusion, this dysregulation of the RAS in renal
tubules is pivotal in the pathogenesis of tubulointerstitial
injury in IgAN. The tubulointerstitial injury could be
ameliorated by a novel therapeutic approach of
sequentially targeting ATR1 and ATR2 expression.
Further in vivo study is warranted to test our laboratory
findings.
PERITONEAL BIOLOGY AND PERITONEAL DIALYSIS
Peritoneal dialysis (PD) is the major renal replacement
therapy in Hong Kong, accounting for 70% of dialysis
modalities. Understanding of the biology of the
peritoneal membrane is essential for successful and
efficient long-term dialysis therapy. The peritoneum
is covered by a mesothelial monolayer beneath which
is a basement membrane and submesothelial layer that
contains collagen, fibroblasts, adipose tissue, blood
vessels and lymphatics. During PD, peritoneal cells
are repeatedly exposed to a nonphysiologic hypertonic
environment with high glucose content and low pH.
Mesothelial cells play an important role in regulating
the inflammatory response in the peritoneal cavity:
they produce proinflammatory cytokines and
chemoattractants. The most marked changes are in
cases of severe and recurrent peritonitis. Conventional
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PD fluids (PDFs) make use of the osmotic gradient
generated by glucose. Years of exposure to PDFs result
in the formation of an avascular layer of interstitial
matrix and plasma proteins in the submesothelial
compact zone and an epithelial-to-mesenchymal
transition (EMT) of mesothelial cells. The fibrotic
process in the peritoneal membrane is developed
following acute and chronic release of inflammatory
mediators related to PD. Chronic changes in the
peritoneum with fibrosis develop after years of PD.
Long-term exposure to PD solutions appears to
increase fibrosis and the probability of ultrafiltration
failure.
D-glucose in PDFs is a reactive compound that
exerts an effect on the mesothelial cells directly or
through its degradation pathway. Glucose upregulates
the synthesis of TGF-β and connective tissue growth
factor (CTGF) by human peritoneal mesothelial cells
(HPMCs) in a dose- and time-dependent manner. The
two pathways of glucose degradation also play an
important role in peritoneal mesothelial biology: (1)
degradation into glucose degradation products (GDPs);
and (2) formation of advanced glycation end-products
(AGEs). Accumulation of AGEs in the peritoneal tissue
promotes expression of various growth factors and
subsequently results in deterioration in ultrafiltration
capacity in PD. Exposure to GDPs leads to enhanced
cytotoxic damage and proinflammatory response in
mesangial cells. In addition, GDPs stimulate the
production of vascular endothelial growth factor
(VEGF) by HPMCs that  enhances vascular
permeability and angiogenesis. Several studies have
investigated the biocompatibility of different PDFs with
various peritoneal cell types. Bicarbonate-buffered
solutions stimulate less production of TGF-β by
cultured HPMCs than conventional PDFs. Mesothelial
cell repair (remesothelialization) after exposure to
GDPs is impaired, independent of D-glucose
concentration. Among other things, the transformation
of epithelial to mesenchymal cells is responsible for
this. We also demonstrated that tight junctions like
ZO-1, occludine and claudin-1 became weak and were
downregulated after incubation with dialysis solution.
Disruption of intercellular tight junction in HPMCs may
occur following downregulation of ZO-1 expression in
which VEGF plays an important role.
HPMCs are biologically active and play different
roles other than local host defense. However, following
exposure to unphysiologic milieu with conventional
PDFs, denudation of the mesothelial monolayer occurs
even within months of commencing PD treatment.
Hence, the chronic inflammatory changes of the
peritoneal membrane may not be due to the cytokines
released by HPMCs. Our latest observations have
strongly suggested the inflammatory role of peritoneal
adipocytes in PD.
Peritoneal adipocytes, previously viewed as less
important in peritoneal physiology during PD, are
ubiquitously found in all peritoneal tissue. Adipose
tissue is abundant in omental or mesenteric peritoneum
but less so in parietal, intestinal and diaphragmatic
peritoneum. In parietal peritoneum, adipocytes lie
deeply under the mesothelium and connective tissue.
During fluid dwell in PD, solutes in PDF move by
passive diffusion through the peritoneal barrier and
come into contact with the adipocytes. Ultrastructural
study demonstrated that a portion of adipocytes
protrudes from the mesothelial surface; thus, omental
adipocytes may come into direct contact with the
dialysate. In addition, the dialysate may also reach
the parietal adipose tissue when there is junctional
damage or denudation of the mesothelial monolayer.
It is therefore logical to postulate that with repeated
exposure to PDFs and the continuous changes in
peritoneal physiology during continuous ambulatory
PD, peritoneal adipocytes will inevitably be
“activated”.
Adipose tissue is a complex organ with functions
far beyond that of an energy storage depot. There is
now compelling evidence to indicate that adipocytes
can mediate various physiologic processes through
secretion of an array of adipokines that include leptin,
adiponectin, resistin, TNF-α, IL-6, TGF-β, and other
growth factors. Moreover, adipocytes express
receptors for leptin, insulin growth factor-1, TNF-α,
IL-6 and TGF-β, and may form a network of local
autocrine, paracrine and endocrine signals. All of these
adipokines have important endocrine functions in
chronic kidney diseases and may also be important
contributors to systemic inflammation in these
patients. In PD patients, this is of special significance
as the initiation of treatment is often associated with
an increase in fat mass that could be associated with
the genetic effect on energy metabolism in addition
to glucose absorption from the PDF. In contrast to
findings in the general population, a number of studies
have suggested that a high body mass index (BMI) is
associated with a better outcome in the renal
population. Critical analysis revealed that the pro-
tective effect from a high BMI is only present in pa-
tients with a normal or high muscle mass. A recent
study indicated that an increased fat mass in PD, like
in other patient groups, may indeed have adverse
metabolic consequences with increased systemic
inflammation and worst survival. Interestingly, there
is a difference in the release of growth factors be-
tween visceral and subcutaneous adipose tissue. The
omental adipose tissue most affected by PD releases
two- to three-fold more IL-6 than subcutaneous
fat tissue. Visceral fat mass correlates significantly
with circulating IL-6 levels but non-visceral fat mass
does not.
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Lately, the potential inflammatory role of
peritoneal adipocytes has been suggested by novel data
on leptin synthesis and leptin receptor expression in
peritoneal tissue. We found that both mRNA and
protein of the full-length leptin receptor are expressed
constitutively in HPMCs. Leptin receptor expression
in mesothelial cells is upregulated by glucose but not
by leptin. In adipocytes, glucose increases the mRNA
expression and synthesis of leptin. The Janus kinase-
signal transducer and activation (JAK-STAT) signal
transduction pathway in mesothelial cells is activated
by either exogenous or adipocyte-derived leptin.
Exogenous leptin induces the release of TGF-β by
mesothelial cells. The TGF-β synthesis induced by
leptin is amplified by glucose through increased leptin
receptor expression. These new findings strongly point
to the notion that peritoneal adipocytes activated by
PDFs exert a proinflammatory effect on mesangial
cells through the release of adipokines and hence
contribute to altered peritoneal physiology and
dysfunction during PD. Hence, pharmacologic
intervention of the proinflammatory action in peri-
toneal adipocytes may represent a novel approach to
prevent peritoneal fibrosis.
In our study of adipocyte culture, we noted the
phenotypic “regression” of adipocytes to pre-adipocytes
that have lost their cellular fat content. It is not well
recognized that fat tissue is an underappreciated source
of stem cells. The differential potential of adipose-
derived cells include cartilage, skeletal muscle, neuronal
cells, hematopoietic cells, endothelial cells and
hepatocytes. Hence, the reprogramming of pre-
adipocytes may potentially be a novel therapeutic
approach in stem cell biology.
EPILOGUE
As practising clinicians, we often realize the crux of
the clinical issue but are frequently frustrated by the
limited options of effective therapy. Expanding our
treatment strategies by understanding the upstream
and downstream events of the pathologic cascade
represents a logical approach in our clinical practice.
The division between scientists and clinicians must
be removed in order to initiate a seamless and holistic
approach for future patient management.
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